$AEYE

AUDIOEYE INC (AEYE): Results of Operations and Financial Condition

AUDIOEYE INC (AEYE) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 aeye-20260813xex99d1.htm EX-99.1 ​ ​ Exhibit 99.1 ​ AudioEye Reports Record Second Quarter 2026 Results Forty-Second Consecutive Period of Record Revenue TUCSON, Ariz. — August 13, 2026 — AudioEye, Inc. (Nasdaq: AEYE) (“AudioEye” or the “Company”) , an industry-leading

Original reporting
Published Aug 13, 2026, 8:10 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 8:14 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$AEYE
Bullish
medium confidence
Mentioned
$AEYE
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$AEYEBullishMed
01

Why it matters

Traders should focus on the raised full-year adjusted EBITDA target (at least $12.7M) and adjusted EPS floor ($0.98), then reconcile them with Q3 revenue and adjusted EBITDA ranges.

02

Market read

This is a company-specific earnings and guidance update with multiple quantified targets, making it actionable for positioning around the earnings call.

03

What to watch

The guidance raise is paired with a relatively narrow Q3 revenue range ($10.85M to $11.05M) and EBITDA range ($3.4M to $3.6M), leaving less room for upside if bookings or litigation costs re-accelerate.

Relevance 7/10Novelty 8/10Timing: after-hours today, ahead of the 4:30pm ET earnings call

Background

AudioEye filed an 8-K with Exhibit 99.1 reporting Q2 2026 financial results and providing Q3 and full-year 2026 outlook.

Company-level read

Ticker impact

$AEYEBullishMedium confidence
Context

AudioEye reported Q2 2026 results and raised full-year adjusted EBITDA guidance, targeting at least $12.7M and $0.98 EPS.

Expected impact

Likely positive bias for AEYE into and after the 4:30pm ET conference call, with follow-through dependent on whether Q3 revenue and EBITDA ranges are viewed as credible.

Evidence & confidence

The filing discloses multiple forward-looking datapoints (Q3 revenue and EBITDA ranges, full-year EBITDA and EPS floors) alongside record sequential ARR growth and improved GAAP net loss versus the prior-year quarter excluding a one-time gain.

Market effects

Supports the narrative that digital accessibility software vendors can scale margins and free cash flow, potentially improving sentiment toward the niche.

No clear regional transmission beyond US small-cap software sentiment.

Limited; the disclosed metrics are company-specific with no stated global regulatory or macro shock.

Counterpoint

Operating expenses rose 23% and litigation expenses increased, so margin durability and cash conversion may be less stable than the guidance implies.

Key entities

  • AudioEye, Inc.

    Nasdaq-listed digital accessibility company reporting Q2 2026 results and raised full-year adjusted EBITDA guidance.

  • Kelly Georgevich

    CEO who stated the company is raising full-year adjusted EBITDA guidance and expects meaningful free cash flow in 2H 2026.

  • Matthew Domeyer

    Appointed CFO effective July 2026, succeeding Kelly Georgevich.

Related articles

$AEYEHighAI 9/10

AudioEye Reports Record Second Quarter 2026 Results

AudioEye (Nasdaq: AEYE) reported Q2 2026 results for the quarter ended June 30, 2026. ARR rose to $42.3M from $41.2M sequentially and 11% YoY. Revenue increased 9% to $10.7M. Adjusted EBITDA was $3.0M. The company raised full-year adjusted EBITDA guidance and expects Q3 revenue $10.85M-$11.05M.

$MRXMedAI 8/10

Marex reports $318m profit for first half

Marex reported record adjusted profit before tax of $318m for the first half, up 79% year on year, and record Q2 adjusted profit before tax of $165.9m. Q2 after-tax profit was $155.3m, including a $35.1m gain from selling Winterflood’s custody business. Marex cited redomiciliation to Bermuda and revenue growth across segments.

$MDLNMed

Medline (MDLN) Q2 2026 Earnings Call Transcript

Medline (MDLN) Q2 2026 call said adjusted EBITDA rose 13% YoY to $1.1B, with higher costs partly offset by a $243M IEEPA tariff refund benefit. Q2 net sales grew 12% to $7.7B. Company raised fiscal 2026 organic sales outlook, but moderated adjusted EBITDA outlook citing Middle East conflict, Tracy warehouse fire, investments, quality remediation, and retail softness.

$ISSCMed

Innovative Aerosystems (ISSC) Q3 2026 Earnings Call Transcript

Innovative Aerosystems (ISSC) reported Q3 FY2026 results in an earnings call. The company said revenue rose about 11% to $20.7 million, with net income of $4.5 million ($0.25 diluted share). Gross margin rose to nearly 52% and adjusted EBITDA grew about 75%. It also discussed the Aiden Displays acquisition, an eVTOL OEM contract, and a Nasdaq ticker change to IA on Aug. 18.

$KRTMedAI 8/10

Karat Packaging (KRT) Q2 2026 Earnings Call Transcript

Karat Packaging (KRT) reported Q2 2026 net sales of $136.3 million, up 9.9% year over year, and gross margin of 56.6% versus 39.6% a year ago. Results benefited from IEEPA tariff refunds, including 1,890 bps to gross margin. Net income rose 168.3% to $29.6 million. The company plans a new Orlando distribution center and guided Q3 sales growth in the low double digits.

$CRLMed

Charles River Laboratories (CRL) Q2 2026 Earnings Call Transcript

Charles River Laboratories (CRL) reported Q2 2026 results, citing a strengthening biopharmaceutical demand environment. DSA net book-to-bill rose to nearly 1.2x for a third straight quarter above 1x. Organic revenue growth returned to 0.1%. Operating margin improved 420 bps sequentially to 20.5% after divestitures. CRL also announced collaborations with Eli Lilly (TuneLab) and Arovella Therapeutics (NGS).